Antisense Therapeutics: Bringing life changing innovative medicines to patients in need скачать в хорошем качестве

Antisense Therapeutics: Bringing life changing innovative medicines to patients in need

Jane King interviews Mark Diamond, Antisense Therapeutics, CEO. https://www.antisense.com.au Segment from TV Show 'Innovators with Jane King'. Innovators with Jane King profile's tech companies and thought leaders in the space. We're showing you a glimpse of the future. (FROM COMPANY WEBSITE) Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company Vision: To serve the needs of our patients and stakeholders to the best of our combined abilities. The Company Mission: To bring life changing innovative medicines to patients in need and to add value for all stakeholders through actively exercising our beliefs of honesty, integrity and collaboration. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.